Tag: Cancer: Lymphoma
CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors
Six of 10 patients remained in minimal residual disease-negative complete remission after treatment
Second Primary Malignancy Risk Increased After Cutaneous B-Cell Lymphoma
Women have increased risk for thyroid, renal, lung cancers; men have highest risk for melanoma, bladder, prostate cancers
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
20 percent of patients treated with Breyanzi achieved a complete response
Risk Stratification Can Predict Outcomes for CAR T-Cell Therapy in Lymphoma
Stratification based on prelymphodepletion C-reactive protein, ferritin can classify patients into high, intermediate, and low risk
ASH: Ibrutinib-Venetoclax Beneficial for Relapsed/Refractory Lymphoma
Improvement seen in progression-free survival for patients with relapsed/refractory mantle cell lymphoma
ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients
Five-year PFS was 28.5 percent and overall survival was 40.3 percent; 40.2 percent of patients did not meet ZUMA-1 eligibility criteria
Psychological Distress Reported for Indolent Non-Hodgkin Lymphomas
Overall, 45.8 percent of patients with iNHL are worried about prognosis; 31.2 percent perseverate on their prognosis
Poor Physical Function Persists in Childhood Cancer Survivors
Findings seen for patients diagnosed with acute lymphoblastic leukemia and non-Hodgkin lymphoma from the 1970s through the 1990s
Lymphoid Reaction Observed in Eczema Patients Receiving Dupilumab
Histopathologic findings included sprinkled distribution of small hyperchromatic lymphocytes in the upper epidermal section
Risks for MDS/Leukemia Increased for Survivors of Common Lymphoid Neoplasms
Risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia elevated, but risks lower in recent years
